Walgreens On Tuesday, he reported fiscal profits and income of the second quarter that exceeded expectations, since the pharmacies retail giant benefits from cost cuts and prepares to be private.
The company is in the process of being deprived of Sycamore Partners in an agreement of approximately $ 10 billion that is expected to close in the fourth quarter of this year. Walgreens withdrew his tax guide 2025 given the pending transaction. In January, he said that he expects a full -year tight gain of $ 1.40 to $ 1.80 per share.
The historical agreement with Sycamore ends the tumultuous Walgreens career as a public company, which began in 1927. The company is closing stores and reduces other costs as it is squeezed by the front winding winds of pharmacy reimbursement, the softest spending for consumers and the competition of its main rival of its rival. CVSsupermarkets and retail chains, and Amazon. He is also dealing with a problematic impulse in medical care.
Walgreens actions increased almost 2% in the negotiation prior to the market on Tuesday.
This is what Walgreens reported during the three -month period that ended on February 28 compared to what Wall Street expected, based on a LSEG analysts survey:
- Profit per action: 63 tight cents compared to 53 expected cents
- Revenue: $ 38.59 billion compared to $ 38 billion expected
“The results of the second quarter reflect the management and improvement of disciplined costs in the medical care of the United States, which were partially compensated by the weakest front-end results in the US retail pharmacy. UU.
“We remain in the early stages of our response plan, and we are still waiting for the creation of significant value to take time, the approach improved and balancing future cash needs with the necessary investments to navigate a changing pharmacy and a retail panorama,” he added.
During the second fiscal quarter, Walgreens reserved sales of $ 38.59 billion, 4.1% more than the same period a year ago, as sales grew in their US retail pharmacy businesses. UU. UU. And international segments.
The company reported a net loss of $ 2.85 billion, or $ 3.30 per share, for the second fiscal quarter. It compares with a net loss of $ 5.91 billion, or $ 6.85 per share, in the period of year and more.
Excluding certain articles, the adjusted profits were 63 cents per action for the quarter.
The results include a $ 4.2 billion charge related to a loss of value of its US retail pharmacy. UU. In the Villagemd Primary Care Clinic chain.
But Walgreens obtained profits of $ 1 billion when collecting at the beginning of some of his actions in Cencora, an organization of pharmaceutical solutions, and benefiting from the profits of his investment in Brightspring, a provider of integral health services in the home and the community. Those are two of Walgreens's main medical care investments.
The company's operational cash flow in the second quarter was reached for $ 969 million in legal payments for opio-related agreements and a dispute with the Everly Health Solutions virtual attention company, which claimed that Walgreens broke the terms of a commercial contract during the COVID-19 pandemic.
